Plus Therapeutics (PSTV) CFO granted RSUs and stock options package
Rhea-AI Filing Summary
PLUS THERAPEUTICS, INC. reported that Chief Financial Officer Andrew John Hugh MacIntyre acquired equity awards consisting of restricted stock units and stock options. He received 349,542 Restricted Stock Units, each representing a contingent right to one share of common stock, and 349,541 stock options with a right to buy common stock.
The RSUs vest in substantially equal 1/12th increments over twelve quarters, beginning on April 1, 2026 with the remaining portions vesting quarterly thereafter. The options vest over four years in substantially equal 1/48th monthly increments on each monthly anniversary of grant and also vest upon a change of control in accordance with his employment agreement.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Sims Andrew John Hugh MacIntyre
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 349,542 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 349,541 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 732,774 shares (Direct);
Stock Option (Right to Buy) — 349,541 shares (Direct)
Footnotes (2)
- F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over twelve quarters in substantially equal 1/12th increments, commencing with 1/12th vesting on April 1, 2026 and the remainder vesting quarterly thereafter.
- F2. The options vest over four years in substantially equal 1/48th increments on each monthly anniversary of the issuance and vest on a change of control in accordance with the Optionee's employment agreement.
FAQ
What insider transactions did PLUS THERAPEUTICS (PSTV) report for its CFO?
PLUS THERAPEUTICS reported that its Chief Financial Officer Andrew John Hugh MacIntyre received equity awards. He was granted 349,542 Restricted Stock Units and 349,541 stock options, both structured to vest over multi-year schedules based on continued service and change-of-control provisions.
How many Restricted Stock Units were granted to the PSTV CFO?
The CFO received 349,542 Restricted Stock Units. Each RSU represents a contingent right to receive one share of PLUS THERAPEUTICS common stock, vesting in 1/12th increments over twelve quarters starting April 1, 2026, with quarterly vesting thereafter tied to ongoing service.
What is the vesting schedule for the PLUS THERAPEUTICS CFO RSU grant?
The Restricted Stock Units vest ratably over twelve quarters. They vest in substantially equal 1/12th increments, with the first 1/12th portion vesting on April 1, 2026 and the remaining RSUs vesting on subsequent quarterly dates, aligning with a three-year service period.
What stock option grant did the PLUS THERAPEUTICS CFO receive?
The CFO received 349,541 stock options labeled as a right to buy common stock. These options vest over four years in substantially equal 1/48th increments each month and are also structured to vest on a change of control under his employment agreement terms.
How do the PSTV CFO stock options vest over time?
The options vest over four years in monthly installments. Vesting occurs in substantially equal 1/48th increments on each monthly anniversary of the issuance date and may fully vest upon a change of control in accordance with the CFO’s employment agreement.
Does the PLUS THERAPEUTICS CFO Form 4 show any stock sales or purchases?
The Form 4 shows only grant or award acquisitions, not open-market buys or sales. It reports awards of 349,542 Restricted Stock Units and 349,541 stock options, both classified as grant or award acquisitions rather than transactional purchases or disposals in the market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
